Amendments to the Specification

Please Amend the specification at the paragraph bridging pg 22-23 and pg 23-24.

At page 22-23, the bridging paragraph

Reverse transcriptase inhibitors figure prominently in current HIV treatments. Examples include nucleoside analogs, such as the 2',3'-dideoxyinosine (ddI)(available as Videx® from Bristol Myers-Squibb). Nucleoside analogs are a class of compoounds known to inhibit HIV, and ddI is one of a handful of agents that have received formal approval in the United States for clinical use in the treatment of AIDS. Like zidovudine (3'-azido-2',3' -dideoxythymidine or azidothymidine [AZT] available from Glaxo Wellcome), zalcitabine (2',3' - dideoxycytidine [ddC] available as Hivid® from Hoffman-La Roche), lamivudine 2'-deoxy-3'-thiacytidine [3TC](Epivir® available from Glaxo Wellcome), Iodenosine (F-ddA available from US Biosciences and stavudine (2',3' -didehydro-2',3'-dideoxythimidine [D4T] available as Zerit® from Bristol Myers-Squibb), ddI belongs to the class of compounds known as 2',3' - dideoxynucleoside analogs, which, with some exceptions such as 2',3'-dideoxyuridine [DDU], are known to inhibit HIV replication, but have not been reported to clear any individual of the virus. Other nucleoside reverse transcriptase inhibitors include adefovir ~~dipivoxil [PMEA], or~~ Preveon® an adenine nucleotide analog from Gilead Sciences), abacavir (1592U89 available ~~as Ziagen®~~ from Glaxo Wellcome~~GlaxoSmithKline~~), lubocavir (a guanosine analog available from Bristol Meyers Squibb), and ~~tenofovir DF, [~~PMPA~~]~~, available ~~as Viread®~~ from Gilead Pharmaceuticals ~~Sciences Inc.~~ New nucleosides include ~~emtricitabine, [~~FTC~~]~~ (Emtricitabine), ~~available as Emtriva® from Gilead Sciences, amdoxovir, [~~DAPD, also known as DXG~~] available from Gilead Sciences~~, F-ddA (Lodenosine, a fluorinated purine nucleoside RTI, and dOTC (BCH-10562). Non-nucleoside reverse transcription inhibitors include nevirapine (Viramune™ available from Boehringer Ingelheim Pharmaceuticals, Inc.), delaviridine (Rescriptor® available from Pharmacia & Upjohn) and efavirenz (available as Sustiva®, from DuPont Merck ~~Bristol Myers Squibb~~).

At pages 23-24, the bridging paragraph:

Of the potential protease inhibitors for use against HIV, compounds such as hydroxyethylamine derivatives, hydroxyethylene derivatives, (hydroxyethyl)urea derivatives, norstantine derivatives, symmetric dihydroxyethylene derivatives, and other dihydroxyethylene derivatives have been suggested, along with protease inhibitors containing the dihydroxyethylene transition state isostere and its derivatives having various novel and high-affinity ligands at the P2 position, including 3-tetrahydrofuran and pyran urethanes, cyclic sulfolanes and tetrahydrofuranylglucines, as well as the P3 position, including pyrazine amides. In addition, constrained "reduced amide"-type inhibitors have been constructed in which three amino acid residues of the polypeptide chain were locked into a g-turn conformation and designated g-turn mimetics. Other alternatives include penicillin-derived compounds and non-peptide cyclic ureas. ~~Suitable~~ Suitable protease inhibitors include Indinavir sulfate, (available as CrixivanTM capsules from Merck & Co., Inc, West Point, PA.), saquinavir (Invirase® and Fortovase® available from Hoffman-LaRoche), ritonavir (Norvir® available from Abott Laboratories) ABT-378 (available from Abott Laboratories), Nelfinavir (Viracept®) ~~from Agouron Pharmaceuticals Inc~~), and GW141 (available from Glaxo Wellcome/Vertex) Tipranavir available from ~~Boehringer Ingelheim GmbH~~ Pharmacia & Upjohn, PD 178390 available from Parke-Davis, ~~atazanavir [~~BMS-23632~~] available as Reyataz®~~ available from Bristol-Myers Squibb~~)~~, DMP-450 available from Triangle, and JE 2147 available from Agouron. New protease inhibitors include ABT-378 (Abbott laboratories), L-756423, DMP-450 and AG1776.